Updated Nov 4, 2026FDA and CMS public dataIndependent · free · not health advice
GxRadar
Drugs/Clopidogrel 75 mg tablet
Blood thinner

Clopidogrel 75 mg tablet

Public data on clopidogrel from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.

$0.0469
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-28%
change over five years
peak $0.1182 in 2014-02
25
approved generic applications (ANDAs) on record for Clopidogrel Bisulfate
16 with a product still marketed · first 2008
Not listed
in FDA's current shortage list
no matching FDA shortage entries

NADAC per unit, monthly

CLOPIDOGREL 75 MG TABLET
Show as table
MonthNADAC per unit ($)
2013-110.10856
2014-020.11816
2014-050.10639
2014-080.11427
2014-110.11224
2015-020.09935
2015-050.09707
2015-080.09190
2015-110.08493
2016-020.07942
2016-050.07942
2016-080.07796
2016-110.07106
2017-020.06781
2017-050.06574
2017-080.06522
2017-110.06962
2018-020.06544
2018-050.06461
2018-080.06385
2018-110.06143
2019-020.06166
2019-050.05980
2019-080.06658
2019-110.06646
2020-020.06871
2020-050.06660
2020-080.06637
2020-110.06326
2021-020.06321
2021-050.06573
2021-080.06888
2021-110.06496
2022-020.06516
2022-050.06521
2022-080.06467
2022-110.06493
2023-020.06248
2023-050.06332
2023-080.06380
2023-110.06356
2024-020.06462
2024-050.05774
2024-080.05954
2024-110.05732
2025-020.05875
2025-050.06073
2025-080.05892
2025-110.05522
2026-020.05169
2026-050.04817
2026-080.04696
2026-110.04691

Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.

Recall records mentioning clopidogrel

openFDA enforcement records, by year reported.

20232
20211
20183
20151

7 records since 2012. A record is one product or lot, not one recall event. Combination products that contain clopidogrel are included.

What these numbers mean

NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.

Most recent recall records

Class IIOngoing
Clopidogrel tablets usp
Reason category: cGMP deviations
FDA recall number D-0513-2023
Class IITerminated
Clopidogrel tablets usp
Reason category: cGMP deviations
FDA recall number D-0380-2023
Class IITerminated
Clopidogrel tablets
Reason category: Sterility / contamination
FDA recall number D-0787-2021
Class IITerminated
Clopidogrel bisulfate tablets
Reason category: Dissolution failure
FDA recall number D-0294-2019
Class IITerminated
Clopidogrel bisulfate tablets
Reason category: Dissolution failure
FDA recall number D-0283-2019

Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.

Articles that mention clopidogrel

6 GxRadar articles cite or discuss this drug.

CLOPIDOGREL · NADAC
Price histories · Data story · 5 min

What pharmacies paid for warfarin and clopidogrel, 2013 to 2026

Federal NADAC data show generic warfarin jumped in 2014 and never returned to its 2013 price, while clopidogrel, generic since 2012, lost more than half its price in two bursts.

The approval pathway · Explainer · 6 min

Reference listed drug, reference standard and basis of submission, explained

Every generic copies one approved product and is tested against another, and they are often not the same pill. How FDA defines the RLD and the reference standard, and what the Orange Book shows for common generics.

Labels & identifiers · Explainer · 6 min

Boxed warnings, FDA's most prominent label warning, explained

What 21 CFR 201.57 requires of a boxed warning, how many prescription labels carry one (about a third, by two counts 14 years apart), and why a generic's box matches the brand's.

Equivalence & alternatives · Explainer · 5 min

Narrow therapeutic index drugs and the tighter test for their generics

Warfarin, levothyroxine, phenytoin and a few other drugs face a stricter generic test scaled to the brand's own variability. How it works, which drugs it covers and where state law adds rules.

The approval pathway · Explainer · 5 min

Pediatric exclusivity and the six months it adds before generics

A brand company that studies its drug in children at FDA's written request can win six more months of protection from generics. How the 1997 incentive works, what it attaches to, and what FDA's own lists show.

PRICE INDEX · 2014 = 100
Benchmarks & how prices are set · Data story · 6 min

The brand-generic gap in NADAC

In CMS's Oct. 28, 2026 cost file, brand tablets and capsules cost pharmacies a median 21 times the matching generic. For amlodipine the multiple was 857. Where the gap is widest, and where it nearly closes.